Seeking Alpha

Here are several reasons Pfizer needs to sharpen its pencil

  • Bolstering its claim that Pfizer's (PFE) offer undervalues its pipeline, AstraZeneca (AZN) releases promising data on its lung cancer drug AZD9291. In a 199-cohort Phase 1 clinical trial, it shrank tumors in 51% of patients and 64% of patients with the T790M genetic mutation, which develops in ~50% of non-small cell lung cancer cases that become resistant to EGFR inhibitors.
  • A Phase 2 trial is underway in patients with the T790M mutation at a daily dose of 80 mg. If all goes well, AZN will submit its regulatory filing as early as 2H 2015.
  • The company believes that AZD9291 could achieve peak sales of $3B.
  • Another promising product is MEDI4736, a cancer immunotherapy known as an anti-PDL-1, currently being tested for non-small lung cancer. The firm believes it could achieve peak sales of $6.5B.
  • Yet another is olaparib, a PARP inhibitor being tested for ovarian cancer. Management believes peak sales could hit $2B.
Comments (1)
  • Willow Street Investments
    , contributor
    Comments (829) | Send Message
     
    The PFE deal only benefits the CEO and not the shareholders. Let PFE's pencil be dull. PFE shareholders get stuck with a tax bill if PFE redomiciles in England.
    15 May, 08:26 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|